All In Biotech

Drug Trial Radar · NCT06673056

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T: A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 18, 2025

Primary completion

Dec 31, 2027

Study completion Jun 1, 2028

Sponsor

Lead sponsor
IntraBio IncIndustry
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Conditions

  • Ataxia-Telangiectasia
  • Ataxia-Telangiectasia (A-T)

Interventions

  • N-Acetyl-L-LeucineDrug

    N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)

  • PlaceboOther

    Matching Placebo Sachet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Scale for the Assessment and Rating of AtaxiaTime frame: End of Period I (week 12) vs. End of Period 2 (week 24)

Locations

11 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • The University of Texas Health (UT Health)

    Houston, Texas

  • University of Cologne

    Cologne, Germany

  • University of Giessen

    Giessen, Germany

  • Comenius University Bratislava

    Bratislava, Slovakia

  • University Hospital L. Pasteur

    Košice, Slovakia

  • Hospital Universitario La Paz

    Madrid, Spain

  • University of Bern

    Bern, Switzerland

  • Royal Papworth Hospital

    Cambridge, United Kingdom

  • University of Nottingham

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.